|
Market Closed -
Nasdaq
21:00:00 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 104.00 USD | +1.06% |
|
+0.13% | +217.46% |
| 11-13 | Deutsche Bank Adjusts Spyre Therapeutics Price Target to $141 From $123, Maintains Buy Rating | MT |
| 11-05 | Deutsche Bank Adjusts Spyre Therapeutics PT to $123 From $127, Maintains Buy Rating | MT |
| Market Cap | 9.88B 8.95B 8.28B 7.47B 14.08B 931B 14.57B 99.45B 39.43B 497B 37.06B 36.28B 1,579B | P/E 2026 * |
-32.8x | P/E 2027 * | -26.5x |
|---|---|---|---|---|---|
| Enterprise Value | 8.98B 8.14B 7.52B 6.79B 12.79B 846B 13.25B 90.39B 35.84B 452B 33.69B 32.97B 1,435B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.91% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SYRE | Delayed | |
CBOE
| SYRE | Real-time | |
|
Tradegate
| 3920 | Real-time | |
|
Boerse Muenchen
| 3920 | Real-time | |
|
Deutsche Boerse AG
| 3920 | Delayed | |
|
Börse Stuttgart
| 3920 | Delayed | |
|
Xetra
| 3920 | Delayed |
Last Transcript: Spyre Therapeutics, Inc.
| 1 day | +1.06% | ||
| 1 week | +0.13% | ||
| Current month | +7.71% | ||
| 1 month | +29.27% | ||
| 3 months | +2.11% | ||
| 6 months | +36.29% | ||
| Current year | +217.46% |
| 1 week | 100.49 |  | 110.64 |
| 1 month | 76.87 | | 110.64 |
| Current year | 28 | | 110.64 |
| 1 year | 23.01 | | 110.64 |
| 3 years | 8.75 | | 110.64 |
| 5 years | 2.66 | | 181.82 |
| 10 years | 2.66 | | 300 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 36 | 26/11/2023 |
Scott Burrows
DFI | Director of Finance/CFO | 49 | 31/08/2023 |
Joshua Friedman
CTO | Chief Tech/Sci/R&D Officer | - | 26/11/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cameron Turtle
BRD | Director/Board Member | 36 | 26/11/2023 |
Tomas Kiselak
BRD | Director/Board Member | 40 | 21/06/2023 |
| Director/Board Member | 36 | 21/06/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Exercice | General Counsel | 86,799 | 0.0984% | ||
| 01/10/26 | Exercice | Chief Financial Officer | 22,500 | 0.0255% | ||
| 01/10/26 | Sell | Chief Executive Officer | -15,000 | 0.0170% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.06% | +0.13% | +359.57% | +921.61% | 9.88B | |
| -2.69% | -0.48% | +51.67% | +69.09% | 66.33B | |
| -0.92% | +7.67% | +14.26% | +90.92% | 60.62B | |
| 0.00% | +0.39% | +20.52% | +98.45% | 55.5B | |
| +0.14% | +2.35% | +13.08% | +109.47% | 47.58B | |
| -2.21% | -2.47% | +18.60% | +36.89% | 43.69B | |
| -2.30% | -10.40% | +167.61% | +776.79% | 37.27B | |
| +2.15% | +1.42% | +15.17% | +56.49% | 36.57B | |
| -2.32% | -2.24% | +75.52% | +52.70% | 32.22B | |
| +2.62% | +5.90% | -36.55% | +406.95% | 26.58B | |
| Average | -0.45% | -0.70% | +69.94% | +261.94% | 42B | |
| Weighted average by Cap. | -0.78% | -0.51% | +44.88% | +180.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -294M -266M -246M -222M -419M -27.72B -434M -2.96B -1.17B -14.81B -1.1B -1.08B -47.01B | -400M -363M -336M -303M -571M -37.75B -591M -4.03B -1.6B -20.17B -1.5B -1.47B -64.02B |
| Net Debt | -899M -815M -754M -680M -1.28B -84.81B -1.33B -9.06B -3.59B -45.3B -3.38B -3.3B -144B | -844M -765M -708M -639M -1.2B -79.62B -1.25B -8.5B -3.37B -42.53B -3.17B -3.1B -135B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | US$104.00 | +1.06% | 746,235 |
| 12/11/26 | US$102.91 | -3.66% | 985,835 |
| 11/11/26 | US$106.82 | +2.24% | 894,998 |
| 10/11/26 | US$104.48 | -4.15% | 1,003,967 |
| 09/11/26 | US$109.00 | +4.95% | 1,393,651 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SYRE Stock
Select your edition
All financial news and data tailored to specific country editions
